1-aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models.

doi:10.1016/0014-2999(91)90894-V

Paper

DOI: 10.1016/0014-2999(91)90894-V

1-aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models.

Published Oct 22, 1991 · Ramon Trullas, Traci Folio, Andrew Young

European journal of pharmacology

Q1 SJR score

105

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Highly Cited

Study Snapshot

1-aminocyclopropanecarboxylates show potential as a novel class of antidepressant/anxiolytic agents, with both oral and parenterally administered compounds showing effective reduction of immobility in animal models.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1016/0014-2999(90)94107-9

Rat pup isolation calls are reduced by functional antagonists of the NMDA receptor complex.

Rat pup isolation calls are reduced by NMDA receptor antagonists and partial agonists, suggesting a new class of anxiolytic agents.

1990·89citations·J. Winslow et al.·European journal of pharmacology

European journal of pharmacology

DOI: 10.1016/0028-3908(90)90115-8

Glycine, glycinamide and d-serine act as positive modulators of signal transduction at the N-Methyl-D-Aspartate (NMDA) receptor in vivo : Differential effects on mouse cerebellar cyclic guanosine monophosphate levels

Glycine, glycinamide, and D-serine positively modulate NMDA receptor signaling, with glycine being the most effective at increasing cerebellar cGMP levels.

1990·36citations·T. Rao et al.·Neuropharmacology

Neuropharmacology

DOI: 10.1016/0920-1211(90)90049-2

Anticonvulsant activity of the NMDA antagonists, d(−)4-(3-phosphonopropyl)piperazine-2-carboxylic acid (D-CPP) and d(−)(E)-4-(3-phosphonoprop-2-enyl) piperazine-2-carboxylic acid (D-CPPene) in a rodent and a primate model of reflex epilepsy

D-CPP and D-CPPene show prolonged anticonvulsant activity after oral administration, suggesting their potential as potential antiepileptic therapies in humans.

1990·87citations·Smita Patel et al.·Epilepsy Research

Epilepsy Research

DOI: 10.1016/0014-2999(90)90204-J

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions.

Functional antagonists at the NMDA receptor complex exhibit antidepressant effects, suggesting that reducing neurotransmission at this receptor complex may represent a new class of antidepressants.

1990·751citations·R. Trullás et al.·European journal of pharmacology

European journal of pharmacology

DOI: 10.1016/0028-3908(90)90125-B

Pharmacological characteristics of cyclic homologues of glycine at the N-methyl-d-aspartate receptor-associated glycine site

Cyclic homologues of glycine show varying pharmacological properties at the NMDA-associated glycine site, with larger ring sizes leading to transitions from agonist to mixed agonist/antagonist to antagonist properties.

1990·65citations·G. B. Watson et al.·Neuropharmacology

Neuropharmacology

DOI: 10.1016/0165-3806(90)90219-O

Sequential appearance of anionic domains in the developing blood-brain barrier.

Anionic sites gradually appear in the developing blood-brain barrier, playing a role in the differentiation of cerebral microvasculature into BBB-type microvessels.

1990·26citations·A. Vorbrodt et al.·Brain research. Developmental brain research

Brain research. Developmental brain research

DOI: 10.1111/j.1471-4159.1990.tb02355.x

N‐Methyl‐D‐Aspartate Recognition Site Ligands Modulate Activity at the Coupled Glycine Recognition Site

NMDA recognition site ligands alter the activity at the coupled glycine recognition site, affecting the potency of glycine agonists and antagonists in modulating [3H]TCP binding.

1990·47citations·W. Hood et al.·Journal of Neurochemistry

Journal of Neurochemistry

DOI: 10.1016/0028-3908(90)90018-M

Neuropharmacological characterization of 1-Aminocyclopropane-1-carboxylate and 1-Aminocyclobutane-1-carboxylate, Ligands of the N-Methyl-D-Aspartate-associated Glycine Receptor

ACC and ACBC show rapid inactivation in the brain, with limited in vivo utility despite their potency at the glycine receptor in vitro.

1990·31citations·Tadimeti S. Rao et al.·Neuropharmacology

Neuropharmacology

DOI: 10.1016/0091-3057(89)90317-1

Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors

1-aminocyclopropanecarboxylic acid shows anxiolytic properties, but is less efficacious than chlordiazepoxide and increases time spent in the middle platform of the plus-maze.

1989·100citations·R. Trullás et al.·Pharmacology Biochemistry and Behavior

Pharmacology Biochemistry and Behavior

Citations

DOI: 10.1016/j.pbb.2024.173858

ANXIOLYTICS: Origins, drug discovery, and mechanisms

Anxiolytics are needed to treat anxiety, but current drugs may not be effective for some patients and may have side-effects and safety issues.

2024·1citation·J. Witkin et al.·Pharmacology Biochemistry and Behavior

Pharmacology Biochemistry and Behavior

DOI: 10.1016/j.pbb.2021.173321

The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders

KRM-II-81 shows potential in treating pharmacoresistant epilepsies, traumatic brain injury, and neuropathic pain with low sedation and potential for seizure sensitization prevention.

2022·35citations·J. Witkin et al.·Pharmacology Biochemistry and Behavior

Pharmacology Biochemistry and Behavior

DOI: 10.1101/2020.08.25.266833

Titrating synapse number to treat MDD in Fragile X Syndrome

Rapid antidepressants alone may not be effective for treating major depressive disorder in Fragile X Syndrome, as they require FMRP expression and GABABR-mediated mTORC1 activity for effective effects.

2020·0citations·Chelcie F. Heaney et al.·bioRxiv

bioRxiv

DOI: 10.1038/s41380-020-00977-z

Role of FMRP in rapid antidepressant effects and synapse regulation

Rapid antidepressants like Ro-25-6981 require FMRP expression and mTORC1-dependent synapse regulation, suggesting they may not be effective for people with comorbid Fragile X Syndrome and major depressive disorder.

2020·6citations·Chelcie F. Heaney et al.·Molecular Psychiatry

Molecular Psychiatry

DOI: 10.1007/s40263-018-0492-x

Convergent Mechanisms Underlying Rapid Antidepressant Action

Ketamine provides rapid-onset antidepressant effects, and future treatments for depression may occur within hours of treatment initiation.

2018·139citations·P. Zanos et al.·CNS Drugs

CNS Drugs